Novo Nordisk A/S (NYSE:NVO) is Dillon & Associates Inc.'s 8th Largest Position

Key Points

• Dillon & Associates Inc. increased its holdings in Novo Nordisk A/S by 2.7% in Q1, making it the fund's 8th largest position, valued at approximately $20.36 million.
• Recent earnings data shows Novo Nordisk reported $0.97 EPS, surpassing expectations, with a significant net margin of 35.60%.
• The company announced a semi-annual dividend of $0.4119 per share to be paid on August 26th, despite a dividend payout ratio of 45.05%.

Dillon & Associates Inc. lifted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 2.7% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 295,114 shares of the company's stock after acquiring an additional 7,638 shares during the quarter. Novo Nordisk A/S accounts for about 3.0% of Dillon & Associates Inc.'s holdings, making the stock its 8th biggest holding. Dillon & Associates Inc.'s holdings in Novo Nordisk A/S were worth $20,363,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Strategic Investment Solutions Inc. IL increased its stake in Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares during the period. Park Square Financial Group LLC bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth approximately $29,000. Transce3nd LLC purchased a new position in shares of Novo Nordisk A/S in the fourth quarter worth $33,000. North Capital Inc. purchased a new stake in Novo Nordisk A/S during the 1st quarter valued at $27,000. Finally, Copeland Capital Management LLC grew its holdings in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after acquiring an additional 255 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $51.06 on Monday. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $139.74. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The company has a market capitalization of $227.98 billion, a price-to-earnings ratio of 14.03, a P/E/G ratio of 1.75 and a beta of 0.63. The company has a 50 day simple moving average of $67.14 and a two-hundred day simple moving average of $71.47.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. The company had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, August 26th. Investors of record on Monday, August 18th will be given a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date of this dividend is Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is 45.05%.

Wall Street Analyst Weigh In

NVO has been the subject of several recent analyst reports. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. HSBC cut Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 target price on the stock. in a research note on Thursday, July 31st. UBS Group lowered Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 5th. Finally, Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of "Hold" and an average price target of $93.67.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.